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We isolated human KB adenocarcinoma cisplatin-resistant (CP-r) cell lines with multidrug-resistance phenotypes because of reduced
accumulation of cisplatin and other cytotoxic compounds such as methotrexate and heavy metals. The uptake of horseradish
peroxidase (HRPO) and Texas Red dextran was decreased several-fold in KB-CP-r cells, indicating a general defect in fluid-phase
endocytosis. In contrast, although EGF receptors were decreased in amount, the kinetics of EGF uptake, a marker of receptor-
mediated endocytosis, was similar in sensitive and resistant cells. However, 40–60% of the
125I-EGF released into the medium after
uptake into lysosomes of KB-CP-r cells was TCA precipitable as compared to only 10% released by sensitive cells. These results
indicate inefficient degradation of internalised
125I-EGF in the lysosomes of KB-CP-r cells, consistent with slower processing of
cathepsin L, a lysosomal cysteine protease. Treatment of KB cells by bafilomycin A1, a known inhibitor of the vacuolar proton pump,
mimicked the phenotype seen in KB-CP-r cells with reduced uptake of HRPO,
125I-EGF,
14C-carboplatin, and release of TCA
precipitable
125I-EGF. KB-CP-r cells also had less acidic lysosomes. KB-CP-r cells were crossresistant to Pseudomonas exotoxin, and
Pseudomonas exotoxin-resistant KB cells were crossresistant to cisplatin. Since cells with endosomal acidification defects are known to
be resistant to Pseudomonas exotoxin and blocking of endosomal acidification mimics the CP-r phenotype, we conclude that
defective endosomal acidification may contribute to acquired cisplatin resistance.
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Cisplatin (CP) is a component of standard treatment regimens for
testicular, ovarian, bladder, cervical, head and neck and small-cell
and nonsmall-cell lung cancers (Ozols and Williams, 1989; Perez,
1998). Adducts of DNA with CP induce apoptosis leading to cell
death (Minn et al, 1995; Simonian et al, 1997). Intrinsic or
acquired resistance of tumour cells to CP undermines its clinical
effectiveness (Niedner et al, 2001). Mechanisms of resistance
include decreased drug accumulation (Shen et al, 2000), changes in
DNA repair proficiency (Fink et al, 1998; Zhen et al, 1992; Chu,
1994; Lai et al, 1995; Johnson et al, 1996), metallothionein (MT II)
(Kelly et al, 1988; Kondo et al, 1995), glutathione-related enzymes
(Moscow and Cowan, 1988; Godwin et al, 1992; Zaman et al, 1995),
stress response proteins (Shen et al, 1995; Hettinga et al, 1997),
proto-oncogenes or apoptosis-related genes, and cancer suscept-
ibility genes (Fanidi et al, 1993; Lowe et al, 1993; DeFeudis et al,
1996; Husain et al, 1998; Moorehead and Singh, 2000). Protein
kinases (PKs) like PKA and PKC have also been associated with
CP-resistance (CP-r) and use of their specific inhibitors has been
demonstrated to increase CP cytotoxicity in resistant tumour cells
(Gosland et al, 1996). Recently, our laboratory (Shen et al, 2000)
reported decreased energy-dependent uptake of
14C-carboplatin by
CP-r cells. Copper transporters have recently been described to be
involved in cisplatin uptake in yeast and mouse (Ishida et al,
2002), and in human cell lines (Katano et al, 2002). However, we
have been unable to demonstrate any alternation in expression of
the copper transporter CTR1 in our CP-r cell lines, and expression
of CTR1 in our cells does not change cisplatin accumulation (data
not shown). It was of interest to evaluate various uptake pathways
in CP-r cells.
Results of the present study demonstrate the reduced uptake of
fluid-phase endocytotic markers by CP-r cells. We also report here
the incomplete degradation of internalised EGF and slow
processing of lysosomal cysteine protease cathepsin L in CP-r
cells. Treatment of normal cells with the vacuolar proton pump
inhibitor bafilomycin A1 mimics the CP-r phenotype in wild-type
cells, suggesting that an endosomal/lysosomal acidification defect
or another similar defect in the endocytic pathway may be
plausible mechanisms contributing to CP-r.
MATERIALS AND METHODS
Cell lines and cell culture
The previously described human epidermoid carcinoma cell line
KB-3-1 (IC50 0.1mgml
1 cisplatin) and its CP-r derivative KB-CP20
(selected for resistance to 20mgml
1 cisplatin in many steps) were
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sused in the present study. These cells were grown as monolayer
cultures in Dulbecco’s modified eagle’s medium (Quality Biologi-
cal, Gaithersburg, MD, USA) containing 4.5gl
1 glucose (Gibco-
BRL, Grand Island, NY, USA), glutamine, penicillin, streptomycin
and 10% foetal bovine serum at 371Ci naC O 2 incubator. The KB-
CP20 cells were maintained in the above culture medium
containing CP (20mgml
1) as described earlier (Shen et al,
1995). Cisplatin was removed from the culture medium 3 days
prior to conducting experiments. KB-CP20-EGFR-cl-6 cells were
cloned from transfectants of KB-CP20 cells with the pcDNA/EGFR
expression vector, and used for studies on EGF binding and
uptake. Pseudomonas exotoxin-resistant cell lines, ET-12, ET-22
and ET-28 (ET: EGF-toxin-resistant cells), were established and
described in detail by Amano et al (1988). These ET cell lines were
up to more than 10000-fold resistant to PE-EGF conjugate in
comparison with their parent wild-type KB-3-1 cells as determined
by a colony-forming assay.
Uptake assays of horse radish peroxidase (HRPO) and
Texas Red dextran-10
For the HRPO assay, KB-3-1 or KB-CP20 cells were seeded in each
well of a six-well plate 18 – 24h before the assay. The next day, the
cells were washed three times with serum-free medium and
incubated at 371C with medium containing 2mgml
1 HRPO type
VI. After various intervals of time, the uptake medium was
removed and the cells were washed several times with ice-cold
phosphate-buffered saline (PBS), and lysed in PBS containing 0.2%
TritonX-100. The cell lysate was centrifuged (12000g)i na
microcentrifuge at 41C and HRPO was assayed in the supernatant
fraction by the method of West et al (1989). For uptake of Texas
Red dextran-10 (Molecular Probes, Eugene, OR, USA), both KB-3-
1 and KB-CP20 cells were incubated with this fluorescence-labelled
marker at 371C for 2h, and then monitored under a laser scanning
confocal microscope (Bio-Rad, Hercules, CA, USA) at a 600
magnification. A time course for influx of Texas Red dextran-10
was performed by incubation of cells with 3mgml
1 of this
fluorescence marker at a desired period of time, and then analysed
by a FACSort flow cytometer (Becton Dickinson, Franklin Lakes,
NJ, USA) equipped with Cell Quest software.
14C-carboplatin uptake assay and metabolic labelling
The uptake of
14C-carboplatin was measured essentially by the
method described earlier (Shen et al, 2000). Briefly, 210
6 cells
were plated in each well of a six-well Petri dish. The next day, the
cells were washed with prewarmed DMEM and incubated with
14C-carboplatin in DMEM (2mCiml
1). After 1h, medium was
removed, cells were washed 3 with ice-cold PBS and harvested
by trypsinisation.
14C-carboplatin taken up by cells was quanti-
tated using a Beckman Liquid Scintillation Counter (LS 2800,
Fullerton, CA, USA) after solubilising them in Formula 989
(Dupont, NEN, Boston, MA, USA). For metabolic labelling, 210
6
cells were plated in each well of a six-well Petri dish. The next day,
the cells were washed twice with methionine-free, cysteine-free
medium containing 2mM glutamine and preincubated in the same
medium for 1h before labelling in the presence of
35S-translabel
(200mCiml
1). After 30min, the cells were washed three times
with ice-cold PBS and either lysed in SDS buffer A (50mM Tris-HCl
pH 7.4, 150mM KCl, 0.5% NP-40 and 0.05% SDS) immediately or
fed with regular serum-free medium. After 30, 60, 120 and 240min,
the culture medium was collected. The cells were washed three
times with ice-cold PBS and lysed. The cell lysate of the 30min
pulse period containing 110
6 TCA precipitable counts, and an
equal volume of lysate were used at the other chase periods. The
lysates were immunoprecipitated with rabbit polyclonal antibody
to the lysosomal cysteine protease cathepsin L as described
previously (Chauhan et al, 1998). Similarly, secreted cathepsin L in
a volume of culture medium proportional to the amount of lysate
from different chase periods was also immunoprecipitated. The
immunoprecipitates were resolved on SDS – PAGE and subjected
to autoradiography as described earlier (Chauhan et al, 1998). The
42kDa unprocessed form of human cathepsin L or its 34 and
26kDa processed forms were quantitated by a phosphorImager
425 (Molecular Dynamics, Sunnyvale, CA, USA).
Surface binding of
125I-EGF
KB-3-1 and KB-CP20 cells were plated in triplicate in 24-well
tissue culture dishes at a cell density of 210
5 cells well
1 in
0.5ml containing 10% FBS. The following day, the cells were fed
with fresh DMEM and incubated for 1h at 371C. Then the cells
were chilled on ice for 30min and
125I-EGF (8nM, specific activity
75Cimmol
1) was added to each well. The incubation was
continued on ice for an additional 2h. Then the medium was
aspirated off, cells were washed three times with ice-cold PBS and
solubilised in 0.5ml of 1 N NaOH, and
125I-EGF bound to the cell
surface was determined by using a mini-gamma counter (LKB,
Gaithersburg, MD, USA). To determine the nonspecific binding of
radiolabelled EGF, cells were incubated with
125I-EGF in the
presence of a 10 M excess of unlabelled EGF and processed
similarly. This value was subtracted from the specific binding. The
nonspecific binding was never observed to be more than 5% of the
specific binding.
Internalisation, degradation and release of
125I-EGF
Measurement of internalisation and degradation of radiolabelled
EGF by CP-r and cisplatin-sensitive (CP-s) cells was performed as
described earlier (Das et al, 1989).
125I-EGF was allowed to bind to
surface receptors at 41C for 2h as described above. While still on
ice, the cells were washed with ice-cold PBS three times and fed
with 1.0ml complete media followed by incubation at 371Ci na
CO2 incubator for 0, 5, 15, 30, 60 and 120min. At the end of each
time period, the medium was saved and total and TCA precipitable
radioactivity was determined. The cells were washed with ice-cold
PBS and incubated on ice for 6min with 1.0ml of mild acid (0.2 M
acetic acid – 0.5 M NaCl, pH 2.5). The acidic medium was carefully
removed and counted (acid-dissociated radioactivity). The re-
maining cell-associated radioactivity was solubilised at 601C with
1.0ml of 1 N NaOH and counted in a gamma counter (non-
dissociated radioactivity).
Drug-sensitivity assay
Dose – response curves were determined by seeding 510
4 cells in
1ml of medium in each well of a 24-well plate. Drugs at desired
concentrations were introduced into the wells at the time of cell
seeding. After 371C incubation for 3 days, cells were counted by a
Coulter Counter. An IC50 was measured as the concentration of
drug reducing the growth of cells to 50% of that in control (drug-
free) medium. A relative resistance factor value for each drug was
calculated by dividing the IC50 value of each cell line by that of the
wild-type KB-3-1 cells. The values are means of triplicate
determinations.
Measurement of endosomal and lysosomal pH
Cells (200ml) at a density of 110
6 cellsml
1 were placed onto an
1818mm coverslip and allowed to grow for 3 days. KB-3-1 and
KB-CP20 cells were incubated with 1.5mM LysoSensor DND-189
(Molecular Probes, Eugene, OR, USA) in DMEM medium for
45min, and then replaced with fresh medium. Acidified compart-
ments were visualised by laser confocal microscopy. pH determi-
nation by LysoSensor-binding fluorescence studies was performed
according to the manufacturer’s instructions. For analysis of
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slysosomal distribution, cells were incubated with 100nM
LysoTracker Red DND-99 (Molecular Probes, Eugene, OR, USA)
for 30min, then monitored under a laser scanning confocal
microscope as described above. For direct measurement of
endosomal pH, cellubrevin pHluorins were applied as described
by Miesenbock et al (1998).
RESULTS
Measurement of fluid-phase endocytosis
To determine nonreceptor-mediated fluid-phase endocytosis, we
measured uptake of HRPO at different intervals of time ranging
from 5 to 120min to assess fluid-phase endocytosis in CS-s (KB-3-
1) and Cs-r (KB-CP20) cells, and the results are given in Figure 1.
We observed a five-fold decrease in the uptake of HRPO by
KB-CP20 cells as compared to their sensitive counterparts. This
difference in HRPO uptake was consistently seen at all intervals of
time ranging from 5 to 120min.
Accumulation of Texas Red dextran-10, another fluid-phase
endocytosis marker, was also significantly reduced in the KB-CP20
cells as compared to the KB-3-1 cells during a period of 2h
incubation as seen in Figure 2A and B. We observed that
accumulation of Texas Red dextran-10 in the KB-3-1 cells was
located mostly at the TGN (Trans-Golgi Network) region, while in
KB-CP20 cells the Texas Red dextran-10 was reduced in amount
and deposited at the cytoplasm near the peripheral membrane,
indicating a dysfunctional uptake pathway for the marker in CP-r
cells. FACS analysis on a time course of up to 7h incubation of
cells with Texas Red dextran-10 indicated a four-fold more uptake
in the KB-3-1 cells (Figure 2C) than in the KB-CP20 cells
(Figure 2D) during the incubation period. A relative semiquanti-
tative measurement based on the data from the FACS analysis is
shown in Figure 2E.
Measurement of EGF binding, uptake, release and
degradation
We used
125I-EGF uptake to measure receptor-mediated endocy-
tosis in KB-3-1 and KB-CP20 cells. The binding of radiolabelled
EGF on the cell surface was at least three-fold less in KB-CP20 cells
as compared to the KB-3-1 cells, indicating fewer functional EGF
receptors on their surface. This result has been confirmed by
quantitation of EGF receptors in the plasma membrane as
determined by Western blot (data not shown). In order to
compensate for the reduced number of EGF receptors on the
surface of KB-CP20 cells, these cells were transfected with EGF
receptor cDNA. A clone (KB-CP20-EGFR-cl-6) with receptor
number more comparable to KB-3-1 cells was used for the
following experiments. As shown in Figure 3A and B, both KB-3-1
and KB-CP20-EGFR-cl-6 cells internalised the majority of the
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Figure 1 Kinetics of HRPO uptake by KB-3-1 and KB-CP20 cells. Cells
were incubated with 2mgml
1 HRP at 371C. After various time intervals,
the cells were washed several times, lysed in PBS containing 0.2% Triton X-
100, and HRP in the cell lysate was assayed. Values expressed are mean
7s.d. from three independent experiments.
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Figure 2 Reduced accumulation of Texas Red dextran-10, a fluid-phase
marker, in CP-r cells. (A, B) Cells were incubated with 10mgml
1 of
Texas Red dextran-10 at 371C for 2h, then monitored under a laser
scanning confocal microscope (Bio-Rad, Molecular Probes, Eugene, OR,
USA) at a x600 magnification. (C, D) A time course of Texas Red dextran-
10 accumulation was performed by FACS analysis. Cells were incubated
with 3mgml
1 of Texas Red dextran-10 at 371C for up to 7h. (E)A
semiquantitative analysis based on the data of Figure 2C and D.
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ssurface bound ligand within 30min (nondissociated radioactivity).
Similarly, the release of radioactive ligand into the culture medium
after internalisation followed similar kinetics. However, after
120min, for KBCP-20EGFR-cl-6 cells 45% of the radioactive ligand
released into the medium, after internalisation, could be pre-
cipitated by TCA compared to only 12% in the case of KB 3-1 cells
(Figure 3C). These results indicate that degradation of internalised
radiolabelled EGF is more efficient in CP-s cells than in the
resistant cells, suggesting that CP-r cells may have a defect in
lysosomal acidification.
Secretion and processing of procathepsin L
Malignantly transformed cells are known to secrete a large amount
of the 42kDa procathepsin L into the culture medium (Miesenbock
et al 1998). To understand if cellular secretion of this protease is
affected by the development of the CP-r phenotype in KB-3-1 cells,
we studied the kinetics of procathepsin L secretion into the culture
medium by KB-3-1 and KB-CP20 cells. Our results demonstrate
that both KB-3-1 and KB-CP20 cells secrete procathepsin L into the
culture medium in comparable amounts (Figure 4A, B). However,
the kinetics of processing of procathepsin L is different in the two
cell lines. In KB-3-1 cells, the unprocessed 34kDa cathepsin L is
detectable in the first 30min of the chase period and the 26kDa
mature cathepsin L appears at 60min. In these cells, the majority
of the 42kDa procathepsin L form is processed to the 26kDa
mature form of cathepsin L by 240min, and the 34kDa form is
barely detectable at this period. In contrast, in KB-CP20 cells the
34kDa band appears after a 60min chase, and the 26kDa mature
cathepsin L is barely detectable even after 240min. At this time in
KB-CP20 cells, all three forms of cathepsin L (42, 34 and 26kDa
bands) are detectable, the 34kDa form being predominant.
However, at 240min, the 26kDa form is predominant in KB-3-1
cells and the other two forms of cathepsin L are barely detectable.
These results indicate that the rate of processing of 42kDa
procathepsin L into its enzymatically active 26kDa mature form is
dramatically slowed in KB-CP20 as compared to the sensitive
parental cells. However, the secretory pathway for procathepsin L
appears to be intact.
Bafilomycin A1 treatment and uptake of
14C-carboplatin
and HRPO
Ligands internalised by receptor-mediated endocytosis may be
degraded by proteases in the lysosomal compartment. The above
results suggested a possible lysosomal defect in the CP-r cells.
Since acidic lysosomal pH plays a very important role in the
processing of proteases and degradation of proteins in this
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Figure 3 Kinetics of
125I-EGF uptake, degradation and release into the
medium by KB-3-1 (A) and KB-CP20 cells (B). Details of the experimental
procedure are given in Materials and Methods. Values are mean 7s.d. from
three independent experiments. (C) Kinetics of TCA precipitable
125I-EGF
release by KB-3-1 and KB-CP20 cells. Total medium at different time points
of
125I-EGF uptake was divided into two equal parts. Total radioactivity was
determined in one half and the radioactivity in the TCA-precipitated
fraction of the remaining half was also determined. Values expressed here
are the mean of two independent experiments.
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Figure 4 Kinetics of human procathepsin L secretion and processing in
KB-3-1 (A) and KB-CP20 (B) cells. Cells were radiolabelled briefly for
30min with Trans-
35S-label and chased for varying time periods (0 –
240min, as shown on the top of the gel panels A and B) in serum-free
medium. At the end of each time period, medium was saved and cells were
lysed after washing with ice-cold PBS. The radiolabelled human
procathepsin L was immunoprecipitated using a polyclonal antibody. The
immunoprecipitates were resolved on SDS – PAGE and subjected to
fluorography. The values given on the left side of the panels indicate the
molecular weight of different forms of cathepsin L in kDa.
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scompartment, we altered lysosomal/endosomal pH by treatment
with bafilomycin A1 and studied its effect on the uptake of
14C–carboplatin by CP-r and CP-s cells. The results are given in
Figure 5A. Treatment with bafilomycin A1 (1mM) resulted in a
four-fold decrease in the accumulation of
14C-carboplatin by KB-3-
1 cells. This treatment resulted in little or no decrease in the
accumulation of
14C-carboplatin in KB-CP20 cells. We observed a 2
– 2.5-fold decrease in the uptake of HRPO (Figure 5B) by
bafilomycin A1 treatment in both CP-r and CP-s cells. These results
demonstrate that blocking of lysosomal/endosomal acidification in
cells has effects similar to the phenotype of CP-r on uptake of
HRPO and
14C-carboplatin in KB-3-1 cells. Additional studies
showed that bafilomycin treatment of KB-3-1 cells also blocked the
degradation of
125I-EGF as was seen in untreated KB-CP20 cells
(data not shown).
Changes of lysosome pH in CP-r cells
A pH-sensitive fluorescent dye LysoSensor DND 198 (Molecular
Probes, Inc., Eugene, OR, USA) was used to determine the
intracellular lysosomal pH in living cells. The intracellular
fluorescence intensity was greatly decreased in the CP-r cells
(Figure 6A, B), consistent with an increase in lysosomal pH in the
resistant cells. Use of LysoTracker Red DND-99, which is a
lysosomal dye not sensitive to pH, showed the presence of
lysosomes in the CP-r cells (Figure 6D), although perhaps
somewhat decreased in number in comparison to the CP-s cells
(Figure 6C). Using the cellubrevin pHluorins, it was found that the
sensitive cells have an average ratio of 1.1 – 1.4 (corres-
ponding to an endosomal pH of 5.5 – 6.0). The resistant cells
have an average ratio of 2.0 – 2.6, corresponding to an endosomal
pH of 7.2 – 7.5 (data not shown), suggesting an alkalinisation of
the endosomes in the CP-r cells.
Crossresistance of CP-r cells and Pseudomonas exotoxin
(PE)-resistant KB cells and reduced accumulation
of
14C-carboplatin
The killing curves shown in Figure 7A indicate that the KB-CP20
cells were about 12-fold more resistant than the KB-3-1 cells to PE.
Furthermore, cell lines previously selected for resistance to
Pseudomonas toxin (ET cells) (Amano et al, 1998) were also more
crossresistant to cisplatin by four-fold compared to the parental
wild-type KB-3-1 cells (Figure 7B). Uptake assays of
14C-carboplatin in these ET cells demonstrate a significant
reduction in accumulation in these ET cell lines (Figure 8).
DISCUSSION
Cisplatin is a potent anticancer drug, but its clinical effectiveness is
undermined by the inherent and acquired resistance of tumour
cells to this drug. Although the mechanism of CP-r has been
postulated to be multifactorial, decreased accumulation of this
drug has been consistently observed in resistant tumour cells
(Naredi et al, 1994). Previously, we and others observed reduced
uptake of cisplatin or its analogue carboplatin in CP-r cells, with
no difference in the efflux of this drug between sensitive and
resistant cells (Loh et al, 1992; Mistry et al, 1992; Shen et al, 2000).
These studies indicate that defective uptake of CP was one of the
mechanisms responsible for the resistance. In the present study,
receptor-mediated and fluid-phase endocytosis were assessed
using the well-characterised ligand EGF to understand the
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Figure 5 Effect of bafilomycin A1 treatment on the uptake of
14C-
carboplatin (A) and HRPO (B) by CP-r and CP-s cells. Cells were washed
twice with prewarmed serum-free DMEM and incubated at 371C with the
same medium in the presence (+) or absence ()o f1mM bafilomycin A1.
After 30min medium was removed and fresh DMEM containing
14C-
carboplatin (2mCiml
1) or HRPO (2mgml
1) with (+) or without ()
bafilomycin A1 was added. Then the incubation was continued at 371Ci na
CO2 incubator. After 1h for
14C-carboplatin uptake and 2h for HRPO
uptake, cells were processed as described in Materials and Methods. Values
are mean 7s.d. from three independent experiments.
Figure 6 Confocal microscopic fluorescence images of lysosomal pH (A,
B) by LysoSensor DND 198 and lysosomes (C, D) by LysoTracker
Red DND-99 in KB-3-1 and KB-CP20 cells. (A, C): KB-3-1 cells; (B, D): KB-
CP20 cells.
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smolecular basis of reduced CP uptake leading to CP-r. Fluid-phase
endocytosis, as measured by uptake of HRP and Texas Red
dextran-10, was found to be reduced in CP-r cells. While receptor-
mediated endocytosis for EGF was intact, trafficking of EGF to
lysosomes and/or lysosomal degradation of EGF appeared to be
defective in CP-r cells.
We have previously reported a pleiotropic defect in the
expression of many cell surface proteins in CP-r cells (Shen et al,
1998). The decreased uptake and cell surface binding of
radiolabelled EGF by CP-r cells observed in the present study
suggests the downregulation of this receptor on the cell surface or
its decreased synthesis in these cells. Western blot analysis
revealed decreased levels of the EGF receptor in CP-r cells
(unpublished data), an observation consistent with our previous
results (Mistry et al, 1992). However, expression of the EGF
receptor in KB-CP20 cells at a level comparable to the KB-3-1 cells
also did not result in a proportionate increase in cell surface
binding of radiolabelled EGF (data not shown). These results
suggest that in addition to the decreased synthesis of EGF receptor,
CP-r cells may also harbour a defect in targeting it to the cell
surface or in membrane protein recycling. In recent studies (Liang
XJ, Shen DW, Garfield S, and Gottesman MM, submitted), we have
clearly demonstrated a defect in cell surface localisation for two
additional cell surface proteins.
In receptor-mediated endocytosis, ligand–receptor complexes
are internalised and transported via clathrin-coated vesicles to the
endosomes. Many endocytosed ligands including EGF dissociate
from their receptor in the acidic environment of endosomes and
are finally degraded in the lysosomal compartment (Maxfield and
Yamashiro, 1991). Approximately 90% of the endocytosed
125I-EGF is degraded into monoiodotyrosine (which cannot be
precipitated by TCA) by human fibroblasts in 0.5–2.0h (Carpenter
and Cohen, 1976). Our results (Figure 3) suggest that the
degradation of endocytosed EGF is not as efficient in KB-CP20
cells as in KB-3-1 cells. Since internalised EGF is degraded in the
lysosomal compartment, decreased degradation in the resistant
cells could be because (i) internalised EGF is not reaching the
lysosomal compartment, (ii) the lysosomal compartment in KB-
CP20 cells does not contain proteases and (iii) functionally inactive
proteases are present in the lysosomes.
We have previously demonstrated that KB-3-1 cells express large
quantities of cathepsin L, a lysosomal cysteine protease, the
majority of which is secreted into the culture medium (Chauhan
et al, 1998). In the present study, we used cathepsin L to compare
the expression of lysosomal proteases in KB-3-1 and KB-CP20
cells, and our results demonstrate that both CP-r and CP-s cells
express and secrete this protease at comparable levels (unpub-
lished data). Thus, these results rule out the possibility of proteases
being absent in CP-r cells and demonstrate that there is no defect
in the secretory mechanism of these cells. Human cathepsin L is
synthesised as a 42kDa preproenzyme and autoprocessed into a
34kDa proenzyme and enzymatically active 26kDa forms in the
lysosomes (Salminen and Gottesman, 1990; Chauhan et al, 1998).
Lysomotropic agents like NH4Cl and chloroquine inhibit the
processing of this enzyme to smaller forms, indicating the
requirement of acidic pH for this purpose (Chauhan S and
Gottesman MM, unpublished results). In the present study, we
observed delayed processing of cathepsin L in the lysosomes of
CP-r cells (Figure 5), consistent with the reduced degradation of
125I-EGF.
Bafilomycin A1, a macrolide antibiotic that has been demon-
strated to inhibit vacuolar type H
+-ATPase, inhibits endosomal
and lysosomal acidification and blocks lysosomal degradation of
EGF in A431 cells (human epidermoid carcinoma cells) (Yoshimori
et al, 1991; Melikova et al, 2001), blocked degradation of
125I-EGF
in KB-3-1 cells. Therefore, since acid lysosomal pH is essential for
proper modification, processing and trafficking of proteins, we
wished to determine whether the inefficient acidification of
endosomal/lysosomal compartment(s) was responsible for the
inefficient degradation of
125I-EGF in KB-CP20 cells. Using a
pH-sensitive fluorescence-labelled probe (LysoSensor DND-189,
Molecular Probes, Eugene, OR, USA), a reduction in lysosomal pH
and intensity of lysosomal staining was detected in KB-CP-r cells
as compared to the KB-3-1 cells. Thus, a defect in lysosomal
acidification may play a role in the improper processing of
cathepsin L as well as inefficient degradation of internalised
125I-EGF in CP-r cells. Additional data also show that the early
endosome compartment in CP-r cells is more basic than in the CP-
s cells, while the Golgi complex appears to have a pH similar to the
CP-s cells. In a recent publication, the intracellular pH of CP-r cells
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PE (A), and human Pseudomonas exotoxin-resistant cell lines ET-12, ET-22
and ET-28 to cisplatin in comparison to their wild-type KB-3-1 cells (B)
were determined as described in Materials and Methods.
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Figure 8 Uptake assay of
14C-carboplatin. Cells were incubated with
14C-carboplatin at 371C for 1h. Radioactivity was measured as described in
Materials and Methods.
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swas also found to be significantly higher than that of the sensitive
parental cells (Murakami et al, 2001).
Low endosomal pH has been demonstrated to be essential for
Pseudomonas exotoxin cytotoxicity in mammalian cells (Pastan
et al, 1992). Inhibitors of endosomal acidification protect cells
from diphtheria toxin and Pseudomonas exotoxin cytotoxicity
(Olsnes and Sandvig, 1988; Pastan et al, 1992). Lyall et al (1987)
isolated human clones of KB-3-1 cells resistant to EGF–
Pseudomonas exotoxin conjugates. In the present study, these
cells were found to be crossresistant to CP (Figure 7A). Similarly,
CP-r cells were found to be crossresistant to Pseudomonas
exotoxin (Figure 7B) and to show reduced accumulation of
14C-carboplatin (Figure 8). These results suggest that the
endosomal/lysosomal acidification defect may be responsible for
some of the observed CP-r in KB-CP20 cells.
Conclusions of this study are in agreement with a previous
report, which demonstrated increased sensitivity of tumour cells to
cisplatin at lower cellular pH (Laurencott et al, 1995). The
involvement of defective vacuolar acidification in CP-r was further
confirmed by the four-fold reduction in carboplatin uptake by
KB-3-1 cells after bafilomycin A1 treatment. In addition to reduced
carboplatin uptake, treatment of KB-3-1 cells with bafilomycin A1
blocked
125I–EGF degradation and HRPO uptake (Figure 5). Our
results clearly demonstrate that CP-r cells, which exhibit
reduced uptake of
14C carboplatin and HRPO, harbour an
endosomal acidification defect (Figures 1–6). Blocking endoso-
mal/lysosomal acidification by bafilomycin A1 in KB-3-1 cells
mimics the CP-r phenotype in terms of
14C-carboplatin and HRPO
uptake. Therefore, we conclude that defective endosomal/lysoso-
mal acidification may, at least, partly be responsible for CP-r due
to its reduced uptake, resulting in less drug reaching the cytotoxic
targets.
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